Antibody (FZD10)

Activation of the non-canonical Dvl–Rac1–JNK pathway by Frizzled homologue 10 in human synovial sarcoma. C Fukukawa, S Nagayama, T Tsunoda, J Toguchida, Y Nakamura, et al. Oncogene (2009), 28 (8), 1110-1120

Inverse correlation of the up‐regulation of FZD10 expression and the activation of β‐catenin in synchronous colorectal tumors. S Nagayama, E Yamada, Y Kohno, T Aoyama, C Fukukawa, H Kubo, et al. Cancer science (2009), 100 (3), 405-412

Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on radiosensitivity. H Hanaoka, T Katagiri, C Fukukawa, H Yoshioka, S Yamamoto, Y Iida, et al. Annals of nuclear medicine (2009), 23 (5), 479-485

Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. C Fukukawa, H Hanaoka, S Nagayama, T Tsunoda, J Toguchida, K Endo, .et al. Cancer science (2008), 99 (2), 432-440

Therapeutic potential of antibodies against FZD10, a cell-surface protein, for synovial sarcomas. S Nagayama, C Fukukawa, T Katagiri, T Okamoto, T Aoyama, N Oyaizu, et al. Oncogene (2005), 24 (41), 6201-6212

Molecular target therapy for synovial sarcoma. C Fukukawa, Y Nakamura, T Katagiri. Future Oncol. (2005),1 (6), 805-812